Takeda Pharmaceutical Co Ltd (TKPHF) Q1 2026 Earnings Call Highlights: Navigating Challenges ...
Cooperating Profit: JPY321.8 billion, a decrease of 15.8% at actual FX or 11.9% at CER.
Reported Operating Profit: JPY184.6 billion, an increase of 11%.
EPS: JPY151 (KPS) and JPY79 (reported EPS).
Adjusted Free Cash Flow: JPY190.1 billion.
Growth and Launch Products Revenue: 50% of total revenue, grew 5% at CER.
GI Segment Growth: 4.9% at CER.
Debt Maturity: Average annual maturity approximately JPY220 billion over the next 3 years.
Warning! GuruFocus has detected 5 Warning Signs with TKPHF.
Release Date: July 30, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Takeda Pharmaceutical Co Ltd (TKPHF) reported positive results from two pivotal phase 3 studies of Oparoxin, which met all primary and secondary endpoints, indicating potential for a new standard of care in narcolepsy type 1.
The company's late-stage pipeline is progressing rapidly, with plans to file for US approval of Oparoxin later this year and regional filings to follow.
Takeda's growth and launch products, which represent 50% of revenue, grew by 5% at constant exchange rates in Q1, indicating strong performance in key areas.
The company executed leveraged neutral bond issuances to streamline its debt maturity profile, securing favorable terms due to high demand.
Takeda's plasma-derived therapies continue to expand, with new approvals in Japan and the US, enhancing their market presence.
Negative Points
Takeda Pharmaceutical Co Ltd (TKPHF) experienced an 8.4% decrease in revenue in Q1, primarily due to the impact of generic erosion on key products.
The company's cooperating profit decreased by 15.8% at actual FX, reflecting challenges in maintaining profitability amidst competitive pressures.
Intensified competition in the inflammatory bowel disease market led to a slower growth rate in the gastrointestinal segment.
The impact of foreign exchange rates was a headwind this quarter, affecting revenue and profit margins.
Some key products, including IG, Etivio, and Kenga, showed weaker performance in Q1, raising concerns about their recovery in subsequent quarters.
Q & A Highlights
Q: The sales of products like Etivio, IG, and Kenga were relatively weak in Q1. Do you expect a recovery for these products in the second quarter? Additionally, what benefits can we expect from the new molecule entering the pipeline after 861 and 360? A: Christophe Weber, CEO, responded that the first quarter was soft and does not reflect the underlying dynamics of their products, which is why they have not changed their guidance for the year. Andrew Plump, President of R&D, added that they expect the performance of these products to improve as market access expands, particularly for NTVO in the US. Regarding the new molecule, it is expected to provide additional benefits and advantages, but specific details were not disclosed.
Q: Can you provide more details on the impact of generic erosion on your financial results and how you plan to mitigate this in the future? A: Milano Furuta, CFO, explained that the loss of exclusivity, particularly for high-margin products like Byance, significantly impacted Q1 results. However, they anticipate this impact to moderate in future quarters as the generic supply situation stabilizes and new product launches gain traction.
Q: What are the expectations for the Ovipraxin launch, and how does it fit into Takeda's overall strategy? A: Andrew Plump, President of R&D, highlighted that Ovipraxin has shown promising results in phase 3 trials for narcolepsy type 1 and is on track to be a first-in-class treatment. The launch is expected to establish a new standard of care and contribute significantly to Takeda's growth strategy by addressing unmet medical needs.
Q: How is Takeda managing its debt profile, and what are the plans for future refinancing? A: Milano Furuta, CFO, stated that Takeda executed leveraged neutral bond issuances to streamline its debt maturity profile. The company has managed to secure favorable terms due to high demand for its bonds and plans to maintain a manageable average annual maturity over the next three years.
Q: Could you elaborate on the strategic importance of the late-stage pipeline and its potential impact on Takeda's long-term growth? A: Andrew Plump, President of R&D, emphasized that the late-stage pipeline, including programs like Zazositinib and Rusvertide, has the potential to deliver transformative benefits to patients. These programs are expected to contribute significantly to Takeda's long-term growth by expanding treatment options and addressing significant unmet needs.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
登入存取你的投資組合
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Is ZIM a Good Shipping Dividend Stock to Buy Now?
ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) is included among the 10 Best Shipping Stocks with Dividends. A fleet of vessels docking at a busy harbor, signaling the company's presence in global marine shipping. ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) ranks among the major players in the cargo shipping industry, operating a fleet of over 130 vessels, including large container ships that move goods for manufacturing and retail clients. Although the shipping sector tends to follow a boom-and-bust cycle, ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) benefits from having a comparatively modern fleet, which helps reduce fuel consumption and maintenance expenses. In addition, the company holds a strong presence on key global trade routes, particularly those connecting Asia and Europe. In the first quarter of 2025, ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) reported a strong cash position. The company's operating cash flow for the quarter came in at $855 million, up from $326 million in the same period last year. Its free cash flow also grew from $787 million to $303 million from the prior-year period. During the quarter, it returned $89 million to shareholders through dividends. The company currently pays a quarterly dividend of $0.74 per share. While we acknowledge the potential of ZIM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
an hour ago
- Yahoo
Old Trump speech falsely linked to South Korea trade deal
Social media posts have recirculated an old video of US President Donald Trump and falsely presented it as depicting him calling South Korean leader Lee Jae Myung a "bad negotiator" after their countries agreed a trade deal. The clip in fact shows Trump criticising then president Barack Obama as he launched his presidential campaign in June 2015. "Trump mocks Lee Jae Myung as a bad negotiator," reads a Korean-language post featuring the clip on Naver Band, a South Korean forum, on July 31, 2025. "[Trump] mocked Lee as soon as the tariff negotiations finished. [Lee] has become a total pushover," it continues. The video shows Trump saying, "The people negotiating don't have a clue. Our president doesn't have a clue. He's a bad negotiator." But its Korean subtitles mistranslate "our president" as "their president". The clip was also shared in similar posts on multiple right-wing South Korean circles on Facebook, as well as on YouTube. "The way that fool Lee acted as he did, no wonder he is being mocked," read a comment on one of the posts. Another said: "An international embarrassment to be used like that, then mocked by the US president." Under the trade deal, the United States will impose a 15 percent tariff on South Korean imports -- down from the previously threatened 25 percent -- in exchange for $350 billion in South Korean investments in US industries and $100 billion in energy purchases (archived link). A keyword search on Google found the clip corresponds to a part of a speech Trump gave on June 16, 2015, when he announced his bid for the presidency (archived link). At around the 18:50 mark of the speech posted in full by CSPAN, Trump makes the comment: "The people negotiating don't have a clue. Our president doesn't have a clue. He's a bad negotiator." This was part of a broader tirade against the Obama administration's trade and foreign policies. Trump then references a prisoner swap involving US soldier Bowe Bergdahl to illustrate his criticism of Obama's negotiating skills. Bergdahl was a US Army sergeant who was captured by the Taliban in 2009 after walking off his post in Afghanistan and was released in 2014 in exchange for five Taliban detainees held at Guantanamo Bay (archived link). "We get Bergdahl. We get a traitor. We get a no-good traitor, and they get the five people that they wanted for years, and those people are now back on the battlefield trying to kill us. That's the negotiator we have," Trump said. A full transcript of the speech published by Time magazine also shows Trump was referring to Obama (archived link). Nowhere in the video or transcript does Trump mention South Korea or Lee Jae Myung. AFP has previously debunked similar instances of Trump remarks and social media posts being misrepresented as references to South Korea.
Yahoo
an hour ago
- Yahoo
Those who invested in Fiamma Holdings Berhad (KLSE:FIAMMA) five years ago are up 134%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Fiamma Holdings Berhad (KLSE:FIAMMA) share price has soared 112% in the last half decade. Most would be very happy with that. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Over half a decade, Fiamma Holdings Berhad managed to grow its earnings per share at 15% a year. This EPS growth is reasonably close to the 16% average annual increase in the share price. That suggests that the market sentiment around the company hasn't changed much over that time. Rather, the share price has approximately tracked EPS growth. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of Fiamma Holdings Berhad's earnings, revenue and cash flow. What About The Total Shareholder Return (TSR)? We've already covered Fiamma Holdings Berhad's share price action, but we should also mention its total shareholder return (TSR). The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Fiamma Holdings Berhad's TSR of 134% for the 5 years exceeded its share price return, because it has paid dividends. A Different Perspective While it's never nice to take a loss, Fiamma Holdings Berhad shareholders can take comfort that their trailing twelve month loss of 3.6% wasn't as bad as the market loss of around 6.1%. Longer term investors wouldn't be so upset, since they would have made 19%, each year, over five years. It could be that the business is just facing some short term problems, but shareholders should keep a close eye on the fundamentals. Before forming an opinion on Fiamma Holdings Berhad you might want to consider these 3 valuation metrics. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
